NMRA (STOCKS)
Neumora Therapeutics, Inc. Common Stock
$0.918500
-0.861500 (-48.40%)
Prev close: $1.780000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Paul L. Berns
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $170.05M
- Employees
- 95
- P/E (TTM)
- -0.69
- P/B (TTM)
- 4.59
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
7
Buy
2
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.30 | $-0.32 | +0.0162 | +5.12% |
|
Dec 2025 (Q4)
|
$-0.35 | $-0.33 | -0.0179 | -5.39% |
|
Sep 2025 (Q3)
|
$-0.32 | $-0.34 | +0.0204 | +5.99% |
|
Jun 2025 (Q2)
|
$-0.33 | $-0.38 | +0.0457 | +12.16% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $745.00K |
| Operating Expenses | $223.08M |
| Research and Development | $162.51M |
| Other Operating Expenses | $60.57M |
| Operating Income/Loss | -$223.08M |
| Income/Loss From Continuing Operations After Tax | -$222.39M |
| Income/Loss From Continuing Operations Before Tax | -$222.34M |
| Income Tax Expense/Benefit | $55.00K |
| Net Income/Loss | -$222.39M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$222.39M |
| Net Income/Loss Available To Common Stockholders, Basic | -$222.39M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.33 |
| Diluted Earnings Per Share | -$1.33 |
| Basic Average Shares | 505,129,000 |
| Diluted Average Shares | 505,129,000 |
| Assets | $153.88M |
| Current Assets | $153.43M |
| Noncurrent Assets | $443.00K |
| Fixed Assets | $32.00K |
| Other Non-current Assets | $411.00K |
| Liabilities | $83.20M |
| Current Liabilities | $30.12M |
| Accounts Payable | $5.06M |
| Wages | $4.82M |
| Other Current Liabilities | $20.24M |
| Noncurrent Liabilities | $53.08M |
| Long-term Debt | $52.96M |
| Other Non-current Liabilities | $119.00K |
| Equity | $70.68M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $70.68M |
| Liabilities And Equity | $153.88M |
| Net Cash Flow From Operating Activities | -$193.40M |
| Net Cash Flow From Operating Activities, Continuing | -$193.40M |
| Net Cash Flow From Investing Activities | $124.43M |
| Net Cash Flow From Investing Activities, Continuing | $124.43M |
| Net Cash Flow From Financing Activities | $72.68M |
| Net Cash Flow From Financing Activities, Continuing | $72.68M |
| Net Cash Flow | $3.71M |
| Net Cash Flow, Continuing | $3.71M |
| Comprehensive Income/Loss | -$222.38M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$222.39M |
| Other Comprehensive Income/Loss | -$56.74M |